Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Dexamethasone for Prevention of Oral Chronic GVHD
NCT00391170Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Nov 2006
- Primary completion
- Feb 2021
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dexamethasone iontophoretic patch in graft-versus-host disease (GVHD) (2 arms), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Participants That Developed Severity Score 3 or Higher Oral Chronic Graft Versus Host Disease (GVHD) at Day 90. Started Nov 2006; status: completed.
02
Drugs
dexamethasone iontophoretic patch
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00391170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00391170.